Using PET/CT imaging to evaluate patients following chemoradiotherapy for anal cancer can alter patient management choices.
Imaging with 18F-FDG PET/CT can aid in evaluation and patient management of anal cancer following initial treatment, according to a study published in the Journal of Nuclear Medicine.
Researchers from France performed a retrospective multicenter study to evaluate the relevance of PET/CT and 18F-FDG for anal cancer after chemoradiotherapy. They assessed the impact on patient care and the predictive value of metabolic response.
The small study included 87 patients who received chemoradiotherapy for anal squamous cell carcinoma. All underwent systematic 18F-FDG PET/CT a median of four months after treatment and were followed for two years with clinical examinations every four months and then every six months thereafter, for a median follow-up of 25 months. The researchers evaluated disease progression by biopsy for all patients if there was local recurrence before surgery.
The results showed that 25 patients relapsed and 13 died. The post-therapy 18F-FDG PET/CT did not show any abnormal 18F-FDG uptake with complete metabolic response (CMR) in 55 patients. Thirty-two patients displayed incomplete response (non-CMR): 15 patients with partial response and 17 with disease progression.
Residual tumor tissue detected by 18F-FDG PET/CT:
Differences between CMR and non-CMR patients were:
The researchers noted that imaging with 18F-FDG PET/CT changed patient management in 14 cases (16%), with relevant modifications in 12 (14%).
They concluded that 18F-FDG PET/CT showed good accuracy in posttreatment evaluation of anal cancer and has a relevant impact on patient management. Moreover, CMR was associated with good survival outcome.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.